 Genmab has an impressive pipeline of proprietary and partnered programs in development. In addition, the company has developed or helped develop five FDA-approved monoclonal antibody therapies. The companys revenue is mostly recurring royalties and milestones through licensing of their novel and innovative technology. This business model creates steady revenue and long-term earnings growth. 